Panel: Beyond the Hype: Scientific & Commercial Lessons from the Obesity Therapeutics Boom

Session details:

The explosive rise of GLP-1 therapies has catapulted obesity into the spotlight—fueling massive investment, shifting payer strategies, and resetting expectations for chronic disease management. But as demand surges and pipelines flood, the sector faces critical questions: What have we learned from the first wave of incretin-based therapies? What’s clinically and commercially sustainable? And where is the science heading next? This panel gathers R&D leaders, investors, and commercial strategists to unpack the real-world lessons behind the headlines—and explore what it will take to sustain innovation and impact in the next phase of obesity and metabolic health therapeutics.

• Beyond GLP-1s: The most promising next-gen targets—GIP, amylin, glucagon, and more.
• Data-Driven Differentiation: What clinical endpoints, patient populations, and outcomes will define success?
• Market Saturation vs. Scientific Innovation: How to stand out in a crowded, high-stakes therapeutic area.
• Muscle Loss & Body Composition: Addressing concerns around lean mass preservation and long-term metabolic health.